Extrinsic-pathway enzyme-linked coagulation assay (EP-ELCA). A clot-based alternative to prothrombin time for measurement of extrinsic pathway factors in plasma.
This solid-phase colorimetric microtiter-plate clotting assay is much more sensitive than standard clotting tests. In enzyme-linked coagulation assay (ELCA), enzyme-labeled fibrinogen and solid-phase fibrinogen are the substrate for thrombin generated in the clotting cascade. We used this assay to measure the factors of the extrinsic pathway by an extrinsic pathway-specific assay (EP-ELCA) and to determine the individual factors of the extrinsic pathway (VII, X, V, II) in plasmas of coumadin-treated and heparin-treated patients, with prothrombin time (PT) values used as a reference. In the ELCA method, samples and controls are incubated on the same plate, eliminating the requirement for pre-standardization of the substrate "plasma" before the factor assay is done. Concentrations of factors are determined by serially diluting sample and control plasmas to yield equivalent activity at given dilutions, a more direct approach for measuring specific factors than determining log concentrations vs log clotting time. Changes in the concentrations of clotting factors are seen before changes are apparent by PT. For coumadin-treated patients, all vitamin K-dependent factors were significantly (P less than or equal to 0.001) less than in normal controls, whereas factor V concentrations were normal, as expected. For patients treated with heparin, concentrations of factors X and VII were less than in normal controls (P less than 0.01) and results for EP-ELCA, II, and V assays were normal. This methodology can readily be automated.
Doellgast
G J
GJ
Department of Biochemistry, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC 27103.
Triscott
M X
MX
Buss
D H
DH
West
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001779:Blood Coagulation Factors / Q000032:analysis*; D001780:Blood Coagulation Tests; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000188:drug therapy; D005165:Factor V / Q000032:analysis; D005167:Factor VII / Q000032:analysis; D005170:Factor X / Q000032:analysis; D005340:Fibrinogen; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009195:Peroxidase; D011516:Prothrombin / Q000032:analysis; D011517:Prothrombin Time; D013927:Thrombosis / Q000188:drug therapy; D014812:Vitamin K / Q000494:pharmacology; D014859:Warfarin / Q000506:poisoning / Q000627:therapeutic use
D001779:Blood Coagulation Factors; D014812:Vitamin K; D014859:Warfarin; D005165:Factor V; D005167:Factor VII; D011516:Prothrombin; D005170:Factor X; D005340:Fibrinogen; D006493:Heparin; D009195:Peroxidase